1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ResMed Inc.

ResMed Inc.

RSMDF
ResMed Inc.US flagOther OTC
17.93
USD
- -
- -
26.01BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.06
1.1
1.2
1.31
1.46
1.64
1.82
2.05
2.2
2.45
2.88
3.19
3.51
3.8
Basic EPS, GAAP
0.21
0.24
0.25
0.25
0.24
0.22
0.28
0.43
0.33
0.53
0.61
0.69
0.95
1.04
Free Cash Flow per Basic Share
0.23
0.22
0.22
0.34
0.24
0.3
0.27
0.48
0.43
0.13
0.38
0.87
1.13
1.19
Dividend per Share
0.07
0.1
0.11
0.12
0.13
0.14
0.15
0.16
0.16
0.17
0.18
0.19
0.21
0.23
Book Value per Share
1.1
1.26
1.41
1.54
1.64
1.7
1.7
1.96
2.12
2.47
2.9
3.4
4.15
4.77
Tangible Book Value per Share
0.9
1.01
0.91
0.24
0.45
0.54
-0.21
0.11
0.39
0.74
0.55
1.04
1.67
2.07
Basic Weighted Avg Shares
1,430
1,415
1,405
1,402
1,414
1,428
1,431
1,443
1,453
1,461
1,468
1,470
1,467
1,459
Sales/Revenue/Turnover
1,514
1,555
1,679
1,839
2,067
2,340
2,607
2,957
3,197
3,578
4,223
4,685
5,146
5,538
Operating Margin (%)
23.43
26.46
24.38
23.7
22.1
23.94
24.4
27.36
28.54
28.01
27.28
29.54
32.79
34.6
Depreciation Expense
78
73
73
87
112
120
151
181
192
194
198
216
236
263
Net Income, GAAP
307
345
353
352
342
316
405
622
475
779
898
1,021
1,401
1,520
Effective Tax Rate (%)
20.25
19.9
19.05
19.83
18.26
39.46
22.02
15.2
46.3
18.85
18.53
19.28
16.5
20.16
Profit Margin (%)
20.28
22.2
21.02
19.17
16.56
13.49
15.52
21.02
14.84
21.78
21.25
21.79
27.22
27.44
Working Capital
875
1,287
1,141
782
1,284
554
589
921
663
1,242
1,609
1,447
2,486
2,713
LT Debt
1
301
301
873
1,079
270
1,259
1,266
758
886
1,548
839
811
554
Total Equity
1,611
1,758
1,587
1,695
1,960
2,059
2,072
2,497
2,886
3,361
4,130
4,864
5,968
6,492
Return on Invested Capital (%)
14.74
16.38
16.63
14.51
12.48
12.16
16.76
18.86
12.5
19.58
18.57
19.21
21.99
21.91
Return on Capital (%)
17.86
17.69
16.41
12.88
10.86
10.89
13.48
16.73
12.17
18.98
18.06
18.08
21.89
21.07
Return on Common Equity (%)
20.86
20.56
18.78
17.04
15.29
13.29
16.62
23.59
16.05
23.29
22.82
22.08
25.3
23.86

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
290
290
289
LT Borrowings
409
404
404
LT Finance Leases
148
154
150
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
146
146
145
Market Capitalization
39,761
39,118
28,681

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,626
3,819
4,064
Cash, Cash Equivalents & STI
1,384
1,417
1,661
Accounts Receivable, Net
907
986
999
Inventories
946
922
912
Total Current Liabilities
1,256
1,248
1,351
Payables & Accruals
798
782
883
ST Debt
290
290
289
Deferred Revenue
168
176
179

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.4%
19.08%
22.69%
Free Cash Flow
38.81%
53.1%
28.34%
Net Income, GAAP
17.77%
21.34%
37.2%
Sales/Revenue/Turnover
11.88%
11.77%
9.84%
Total Cash Common Dividend
7.09%
6.73%
10.12%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,102
1,163
1,197
1,223
4,685
2025
1,225
1,282
1,292
1,348
5,146
2026
1,336
1,423
1,431
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.14
0.2
0.2
0.69
2025
0.21
0.23
0.25
0.26
0.95
2026
- -
0.27
0.27
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.05
0.05
0.05
0.19
2025
0.05
0.05
0.05
0.05
0.21
2026
- -
0.06
0.06
- -
- -

Company Description

APIChat
CEO
Michael J. Farrell
Full Time Employees
10,140
Sector
Healthcare
Industry
Medical - Devices
Address
9001 Spectrum Center Boulevard San Diego CA United States of America 92123
IPO Date
Mar 13, 2013
CIK
0000943819
Website
resmed.com
Similar Companies
Outset Medical, Inc. (OM)
Excelsior Medical Co., Ltd. (4104.TW)
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ)
Aquarius Surgical Technologies Inc. (ASTI.CN)
LexaGene Holdings Inc. (LXXGF)
Micro Imaging Technology, Inc. (MMTC)
Business
ResMed Inc. (NYSE: RMD; ASX: RMD) develops, manufactures, distributes and markets cloud-connected medical devices, digital health technologies and software-as-a-service platforms that diagnose, treat and manage sleep-disordered breathing including obstructive sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease and other chronic respiratory conditions; core products encompass sleep and respiratory devices such as AirSense and AirCurve CPAP/APAP systems, Lumis and Astral ventilation devices, AirFit masks and accessories including nasal pillows, full-face and nasal options with integrated humidification and remote monitoring; software solutions comprise AirView for healthcare providers offering patient monitoring, adherence tracking and data analytics, myAir for patient self-engagement with over 8.8 million users, and out-of-hospital SaaS platforms supporting homecare providers and caregivers. Founded in 1989 in Sydney, Australia by Dr. Peter Farrell to commercialize continuous positive airway pressure technology, the company, headquartered in San Diego, California, operates manufacturing facilities in Australia, Singapore, Malaysia and the United States, with direct sales and distribution networks serving over 140 countries including strong presence in the United States, Canada, Latin America, Europe and Asia. In recent developments, ResMed acquired VirtuOx in May 2025, a leading independent diagnostic testing facility providing at-home sleep, respiratory and cardiac testing to enhance virtual care pathways and diagnostic access; the company reported fiscal year 2026 first-quarter revenue of $1.34 billion up 9% year-over-year with non-GAAP gross margin expansion of 280 basis points, launched the Sleep Institute for clinical and policy innovation in sleep health, received Red Dot Design Awards for its AirTouch N30i mask, increased its quarterly dividend by 13% to $0.60 per share, and appointed Nicole Mowad-Nassar to its board while announcing leadership transitions.

Company News

APIChat